Suomalaisnaiset hullaantuivat hormonien k ytt n

Article Abstract:

Every second Finnish woman between 50-54 years is using hormonal preparations. Their sales have more than doubled in the 1990's and are expected to rise as the number of middle-aged women increases. The value of sales has also increased as new preparations are more expensive. Gynecologists estimate that the popularity of estrogene preparations is due to higher level of education, health education and the demands of working life. Hormonal treatment is used most frequently in the greater Helsinki area. In Europe, only the Icelandic and Swedish women use more hormonal preparations than the Finnish women. The pharmaceutical companies use youth and vanity as means of marketing hormonal preparations. A typical woman using hormones is an active clerical employee who lives in a town and works in an office, is unprejudiced and conscious of her health.

Comment:

Finland: Every second Finnish woman between 50-54 years is using hormonal preparations, reflecting strong sales of hormone drugs

Market information - general, Hormone Preparations, Hormones

---

Orionin uutuudella my t tuulta EU:ssa

Article Abstract:

The EU's pharmaceutical product committee of the pharmaceutical control board has decided to recommend that the Finnish Orion's new medicine, entakapon, for the Parkinson disease be granted a sales permission. Orion says that the recommendation applies to both entakapon brand names 'Comtess' and 'Comtan'. The first one Orion sells itself, for the latter they have a marketing agreement with the Swiss Novartis. The EU Commission is estimated to grant the actual sales permission in Sept-Oct 1998. Orion will begin selling the products at least in Germany, Great Britain and Sweden as soon as the permission is granted.

Comment:

EU's pharmaceutical prod committee of pharmaceutical control board grants co's entakapon for Parkinson disease sales permission

Government regulation (cont), Orion Oyj

---

Suomalainen Orion my h styi Parkinson-markkinoilta

Article Abstract:

The Finnish pharmaceutical company Orion has been outperformed by the Swiss competitor Roche in the market introduction of a drug for the treatment of Parkinson's disease. Roche has started to sell tolkaponi, while Orion is yet waiting for a sales permit for its equivalent, entakaponi. Both drugs fight the Comt enzyme and boost the impact of the basic drug. The drug of Orion is the first original drug fully developed in Finland. Orion has agreed on marketing cooperation of the Swiss company Novartis.

Comment:

Outperforms Finnish competitor Orion in the market introduction of a drug for the treatment of Parkinson's disease

Strategy & planning, Switzerland, Orion (Tryon, North Carolina), Roche Holding AG

Similar abstracts:

• Abstracts: Survival is its strong point. In stretching dollars, shopping in Singapore may help, Visa finds. Comic books become a new venue for some marketers in Hong Kong
• Abstracts: Valtion Soneran myyminen aloitetaan lokakuuss Suomi perii ylipainomaksua ven l isrekoilta Valtion velka supistuu kovaa vauhtia
• Abstracts: Enso ja Stora yhdistym ss mets j tiksi Matkapuhelin on menossa rahakortin reviirille Suomalaisten ansiotaso aleni loppuvuodesta
• Abstracts: Suomen vienti Aasian kriisimaihin supistunutyli kolmanneksen

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.